Baxdrostat lowers 24-hour ambulatory blood pressure in resistant hypertension

Key takeaways:

• Baxdrostat reduced 24-hour ambulatory blood pressure in patients with treatment-resistant hypertension.
• Full data from the Bax24 trial will be presented at the American Heart Association Scientific Sessions.

Baxdrostat improved ambulatory 24-hour average systolic blood pressure at 12 weeks compared with placebo in patients with treatment-resistant hypertension, AstraZeneca reported.

The positive topline results of the Bax24 phase 3 trial of baxdrostat 2 mg, an aldosterone synthase inhibitor, were announced in a company press release.

The trial included 218 patients with treatment-resistant hypertension and had a primary endpoint of change in ambulatory 24-hour average systolic BP between baseline and 12 weeks, according to the release.

The company reported baxdrostat was generally well tolerated, with a safety profile consistent with the BaxHTN trial.

“The Bax24 results show that a once-daily baxdrostat regimen can deliver highly clinically meaningful reductions in 24-hour systolic blood pressure, including in the morning when patients are at greater risk of heart attack and stroke,” Bryan Williams, OBE, MD, FMedSci, professor and chair of medicine at University College London and chief scientific and medical officer at the British Heart Foundation, said in the press release. “These results are groundbreaking and together with the BaxHTN results mean we have the potential to change our treatment approach for the many patients whose hypertension remains uncontrolled despite current therapies.”

As Healio previously reported, in BaxHTN, a trial of 796 adults with seated systolic BP of 140 mm Hg to 170 mm Hg despite treatment with up to three or more antihypertensive medications, the addition of baxdrostat on top of background antihypertensive therapy was associated with substantial reductions in seated systolic BP at 12 weeks among patients with uncontrolled or resistant hypertension.

The full results of Bax24 will be presented in a late-breaking session at the American Heart Association Scientific Sessions in November, according to the release.

‘);
notification.css({
‘position’: ‘fixed’,
‘top’: ’20px’,
‘right’: ’20px’,
‘background’: ‘#373D3F’,
‘color’: ‘white’,
‘padding’: ’10px 15px’,
‘border-radius’: ‘5px’,
‘z-index’: ‘9999’,
‘font-size’: ’14px’,
‘box-shadow’: ‘0 2px 8px rgba(0,0,0,0.2)’
});

$(‘body’).append(notification);

// Fade out and remove after 3 seconds
setTimeout(function () {
notification.fadeOut(300, function () {
notification.remove();
});
}, 3000);
}
//# sourceURL=social.js